NCT02394015View on ClinicalTrials.gov

Retrospective Study to Analyze the Efficacy and Safety of Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), According to SmPC

CompletedOBSERVATIONAL
Enrollment

90

Participants

Timeline

Start Date

May 6, 2013

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2017

Conditions
Ovarian Epithelial Cancer Recurrent
Interventions
DRUG

Trabectedin and Pegylated Liposomal Doxorubicin

Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), according to SmPC from October 28, 2009 to October 31, 2014

Sponsors

Collaborators (1)

PharmaMar
All Listed Sponsors
collaborator

PharmaMar

INDUSTRY

lead

Grupo Español de Investigación en Cáncer de Ovario

OTHER

NCT02394015 - Retrospective Study to Analyze the Efficacy and Safety of Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), According to SmPC | Biotech Hunter | Biotech Hunter